Logo image of ALLR

ALLARITY THERAPEUTICS INC (ALLR) Stock Price, Quote, News and Overview

NASDAQ:ALLR - Nasdaq - US0167445008 - Common Stock - Currency: USD

0.9535  +0.01 (+1.44%)

After market: 0.9535 0 (0%)

ALLR Quote, Performance and Key Statistics

ALLARITY THERAPEUTICS INC

NASDAQ:ALLR (2/21/2025, 8:00:53 PM)

After market: 0.9535 0 (0%)

0.9535

+0.01 (+1.44%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High264
52 Week Low0.9
Market Cap4.22M
Shares4.43M
Float3.69M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO12-21 2021-12-21


ALLR short term performance overview.The bars show the price performance of ALLR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

ALLR long term performance overview.The bars show the price performance of ALLR in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ALLR is 0.9535 USD. In the past month the price decreased by -27.77%. In the past year, price decreased by -99.59%.

ALLARITY THERAPEUTICS INC / ALLR Daily stock chart

ALLR Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About ALLR

Company Profile

ALLR logo image Allarity Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2021-12-21. Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The firm is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. The company has in-licensed the intellectual property rights to develop, use and market stenoparib. Its DRP companion diagnostic platform is a predictive biomarker technology that employs complex systems biology and bio-analytics with a clinical relevance filter to bridge the gap between in vitro cancer cell responsiveness to a given therapeutic candidate and in vivo likelihood of actual patient benefit from that therapeutic candidate. Its DRP companion diagnostic platform provides a gene expression signature, which reveals whether a specific tumor in a specific patient is likely to respond to one of its therapeutic candidates.

Company Info

ALLARITY THERAPEUTICS INC

24 School St., 2Nd Floor

Boston MASSACHUSETTS US

Employees: 6

Company Website: https://allarity.com/

Investor Relations: https://allarity.com/investors/

Phone: 14014264664

ALLARITY THERAPEUTICS INC / ALLR FAQ

What is the stock price of ALLARITY THERAPEUTICS INC today?

The current stock price of ALLR is 0.9535 USD. The price increased by 1.44% in the last trading session.


What is the ticker symbol for ALLARITY THERAPEUTICS INC stock?

The exchange symbol of ALLARITY THERAPEUTICS INC is ALLR and it is listed on the Nasdaq exchange.


On which exchange is ALLR stock listed?

ALLR stock is listed on the Nasdaq exchange.


What is ALLARITY THERAPEUTICS INC worth?

ALLARITY THERAPEUTICS INC (ALLR) has a market capitalization of 4.22M USD. This makes ALLR a Nano Cap stock.


How many employees does ALLARITY THERAPEUTICS INC have?

ALLARITY THERAPEUTICS INC (ALLR) currently has 6 employees.


What are the support and resistance levels for ALLARITY THERAPEUTICS INC (ALLR) stock?

ALLARITY THERAPEUTICS INC (ALLR) has a resistance level at 1.49. Check the full technical report for a detailed analysis of ALLR support and resistance levels.


Should I buy ALLARITY THERAPEUTICS INC (ALLR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ALLARITY THERAPEUTICS INC (ALLR) stock pay dividends?

ALLR does not pay a dividend.


What is the Price/Earnings (PE) ratio of ALLARITY THERAPEUTICS INC (ALLR)?

ALLARITY THERAPEUTICS INC (ALLR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-933.21).


What is the Short Interest ratio of ALLARITY THERAPEUTICS INC (ALLR) stock?

The outstanding short interest for ALLARITY THERAPEUTICS INC (ALLR) is 13.25% of its float. Check the ownership tab for more information on the ALLR short interest.


ALLR Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ALLR Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ALLR. The financial health of ALLR is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALLR Financial Highlights

Over the last trailing twelve months ALLR reported a non-GAAP Earnings per Share(EPS) of -933.21. The EPS increased by 99.71% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -95.31%
ROE -149.82%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%99.43%
Sales Q2Q%N/A
EPS 1Y (TTM)99.71%
Revenue 1Y (TTM)N/A

ALLR Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 43% to ALLR. The Buy consensus is the average rating of analysts ratings from 6 analysts.


Ownership
Inst Owners2.36%
Ins Owners16.8%
Short Float %13.25%
Short Ratio0.22
Analysts
Analysts43.33
Price TargetN/A
EPS Next Y99.94%
Revenue Next YearN/A